Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0020473 (hyperlipidemia)
 15,891 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The 2 principal factors implicated in late kidney allograft failure are chronic rejection (also called chronic allograft nephropathy) and death of the patient with a functioning graft (mainly from cardiovascular causes). Despite lifelong immunosuppression of the recipient, immunological responses remain the leading factor in the pathogenesis of chronic rejection and both cellular and humoral immune mechanisms have been shown to play important roles. In this review, we highlight the relevance of humoral mechanisms of rejection to the pathogenesis of late allograft loss. Non immunological factors, such as donor organ quality, initial ischemic injury, calcineurin inhibitor (CNI) toxicity, hypertension, and hyperlipidemia, also contribute to progressive chronic allograft injury, but will not be reviewed in detail here. Possible strategies to stabilize or improve allograft function in patients with already established "chronic rejection/chronic allograft nephropathy" (CR/CAN) are the addition of mycophenolate mofetil (or sirolimus) with or without a reduction of cyclosporine dosage, or conversion from cyclosporine to tacrolimus. However, prospective randomized clinical trials are needed to test the efficacy of these strategies. A major current challenge for transplant physicians is to develop regimens that prevent CR/CAN, since, once established, the process typically progresses inexorably to renal allograft loss in most recipients. Evidence is now accumulating that new immunosuppressive regimens must control not only T cell but also B cell responses (i.e. limit antidonor antibody production) in order to prevent CR/CAN and improve long-term allograft survival.
 ...
PMID:The problem of late allograft loss in kidney transplantation. 1277 62

CAN refers to the progressive decline of renal function seen in some renal transplant recipients in association with alloantigen-dependent and alloantigen-independent factors. Hyperlipidemia is a known risk factor for cardiovascular disease and CAN in adult renal transplant recipients, whereas no data exist in the pediatric transplant population. In this cross-sectional study, 62 renal transplant recipients (32 CAN vs. 30 non-CAN) aged 5-18 yr and with the mean follow-up time of 48 months (9-93) after transplantation were evaluated for lipid profile and renal function tests. Hyperlipidemia has high prevalence in our patients both pre- and post-transplantation. Furthermore, hypercholesterolemia and high-LDL cholesterol levels have significant association with CAN (p = 0.019 and p = 0.039, respectively). In pediatric recipients, hyperlipidemia and particularly hypercholesterolemia have significant association with CAN and adults may need specific therapy.
 ...
PMID:Clinical correlation between dyslipidemia and pediatric chronic allograft nephropathy. 1850 82